Karen Bernstein is the co-founder and chairman of BioCentury, which provides business-oriented information services to a global audience of life science executives and investors from offices in the U.S. and Europe. She is a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain, and at at Codiak Biosciences Inc., which is engineering exosomes to target new therapeutic spaces. She is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI’s School of Pharmacy. She serves on the board of overseers of Scripps Research. In 2005, she was inducted into the Biotechnology Hall Fame, awarded for her lifetime contribution to the biotech community. Karen Bernstein also received the Special Recognition Award at the American Liver Foundation’s Salute to Excellence in 2007, honouring her outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards. She holds a PhD in political science from Stanford University, and a Bachelor of Arts in politics and history from Brandeis University. LinkedIn
Managing Director and Partner at Sinfonie Life Science Management GmbH and Chairman of the Board of Directors at Injex Pharma AG. Peter has a PhD in Biology and Chemistry from the Ludwig-Maximilians Universität in München and is co-founder and chairman of the executive board of BIO-Deutschland, an independent organization representing the interests of the German biotechnology industry. From 2001 to 2009 he was member of European Biopharmaceutical Enterprises (EBE), and its president from 2003 to 2006. He has been a Board Member of EuropaBio since June 2010, and a Member of the Board of Trustees of Bayern Innovativ GmbH. Peter is also a mentor and tutor at the Bavarian Elite Academy, and a member of the Supervisory Board of the University of Augsburg’s MBA program. LinkedIn
Prof. Andrew Porter
Professor of Medical Biotechnology, University of Aberdeen, Scotland and Director of the Scottish Biologics Facility. Andrew is also the CTO of the biologics company Elasmogen Ltd with programs in ophthalmology, inflammation and oncology. He was the founder and CSO of Haptogen Ltd. until it was acquired, in October 2007, by Wyeth Inc. In 2005 he was made the Ernst and Young Plc, UK Science and Technology Entrepreneur of the Year. In 2006 he was became a Fellow of the Royal Society of Edinburgh and VP Business at the RSE in 2019. Andrew has been on the Board of NovaBiotics Ltd since 2009. NovaBiotics recently announced the successful completion of its Phase 2b Cystic Fibrosis trial for Lynovex™ and won EuropaBio’s Most Innovative SME Award in 2017. Outside of bioscience, and with a team of young industry savvy entrepreneurs, Andy has established a portfolio of award winning cocktail bars (top 100 in the world) and opened Langstrane Liquor Ltd in 2015, Aberdeen’s first gin distillery for 100 years. Andy is a graduate of St Andrew’s University, Scotland. LinkedIn
Debora Dumont is Managing Partner and co-founder of Bioqube Ventures. In 2016, Bioqube Ventures partnered with Janssen Pharmaceutica NV to act as the independent management team leading the Belgium-based JLINX incubator. Bioqube Ventures ran the day to day operations of JLINX, including m anaging the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies and supporting the overall scale-up of the new initiative. In March 2018, JLINX became part of the global Johnson & Johnson Innovation network, transitioning into the first JLABS in Europe and the 10th JLABS in the world. Debora previously served as Head of Health & Care at LRM, a Belgium-based private equity and venture capital firm. In this position, she served as a board member on several biotech companies and was involved in a series of international venture capital transactions. Prior to joining LRM, Debora was a business developer at the Biomedical Research Institute of Hasselt University and manager of the life sciences cluster organization LifeTechLimburg (now Healthy Aging). Debora has a PhD in Biomedical Sciences from Hasselt University and holds a Master’s degree in Bioscience Engineering from K.U. Leuven. Debora is director at the Limburg Cancer Foundation. LinkedIn
Dr. Birner, TVM Capital, is responsible for TVM Captital’s overall investment strategy and fund operations in North America and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently serves as Chairman of the board of directors of CENTOGENE AG, SpePharm Holdings BV, leon nanodrugs GmbH, and AL-S Pharma AG. He is also a member of the board of directors of Proteon Therapeutics Inc., Noxxon Pharma and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Argos Therapeutic, Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development. Before starting his professional career in business, he earned substantial academic merits, including a position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree in biochemistry at LMU; his doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School. LinkedIn
Joanna Dupont-Inglis is the Secretary General of EuropaBio, the European Association of Bioindustries. Since arriving in 2009, Dupont-Inglis has worked with the Associations healthcare, agricultural and industrial biotech sectors, as well as with its National Associations Council and SME Platform. Prior to her current role, Joanna was Director for the Industrial Biotech sector for several years, during which time she helped lead industry efforts to create the first €3.7 billion Bio-Based Industries Joint Undertaking (BBI JU), chaired the EU Bioeconomy Stakeholder’s Panel and was a board member of SusChem. Before arriving at EuropaBio, she has been working for two Brussels-based consultancies, in the environmental, agricultural, healthcare, development and energy efficiency sectors. LinkedIn
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.